Advertisement

Liver Diseases pp 407-426 | Cite as

Assessment of Liver Function

  • Zain MoosviEmail author
  • Felix H. Lui
  • Douglas Nguyen
Chapter

Abstract

This chapter explores various liver pathologies and their respective laboratory test abnormalities. Particular emphasis is placed on viral hepatitis, in addition to alcohol-induced, metabolic, and cholestatic liver disease. The chapter concludes with a discussion on the numerous complications of chronic liver disease with a focus on diagnosis and management, followed by a brief look into the future of hepatobiliary diagnostic workup.

Keywords

Hepatitis Metabolic liver disease Cirrhosis Alcohol-induced liver disease Hepatocellular carcinoma 

References

  1. 1.
    Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol. 2013;19:6398.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Raymond GD, Galambos JT. Hepatic storage and excretion of bilirubin in man. Am J Gastroenterol. 1971;55:135.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Schmid R, Diamond I, Hammaker L, Gundersen CB. Interaction of bilirubin with albumin. Nature. 1965;206:1041.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    VanWagner LB, Green RM. Evaluating elevated bilirubin levels in asymptomatic adults. JAMA. 2015;313:516–7.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Karmen A, Wroblewski F, Ladue JS. Transaminase activity in human blood. J Clin Invest. 1955;34(1):126–31.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Moussavian SN, Becker RC, Piepmeyer JL, et al. Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver disease. Dig Dis Sci. 1985;30:211.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Cohen JA, Kaplan MM. The SGOT/SGPT ratio-an indicator of alcoholic liver disease. Dig Dis Sci. 1979;24:835.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. Indian J Clin Biochem. 2014;29(3):269–78.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev Clin Lab Sci. 1980;12:1.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Lum G, Gambino SR. Serum gamma-glutamyl transpeptidase activity as an indicator of disease of liver, pancreas, or bone. Clin Chem. 1972;18:358.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology. 1988;8:385.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Farrugia A. Albumin usage in clinical medicine: tradition or therapeutic? Transfus Med Rev. 2010;24(1):53–63.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Eschar J, Rudzki C, Zimmerman HJ. Serum levels of 5′-nucleotidase in disease. Am J Clin Pathol. 1967;47:598.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Hill PG, Sammons HG. An assessment of 5′-nucleotidase as a liver-function test. Q J Med. 1967;36:457.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore). 1992;71:139.CrossRefGoogle Scholar
  17. 17.
    Gibbs K, Walshe JM. A study of the caeruloplasmin concentrations found in 75 patients with Wilson’s disease, their kinships and various control groups. Q J Med. 1979;48:447.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005;7:26.CrossRefGoogle Scholar
  21. 21.
    Marks PW. Hematologic manifestations of liver disease. Semin Hematol. 2013;50:216.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Johnston DG, Alberti KGMM, Binder C, Faber OK, Wright R, Orskov H. Hormonal and metabolic changes in hepatic cirrhosis. Horm Metab Res. 1982;14:34–9.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. 1967;2:1051–6.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol. 1978;70:248.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    American College of Physicians. Gastroenterology and Hepatology. MKSAP: Medical Knowledge Self-Assessment 18. Philadelphia, PA: American College of Physicians. p. 50. isbn:978-1-938245-50-3 19881989.Google Scholar
  26. 26.
    Sahani DV, Sanjeeva PK. Imaging the liver. Oncologist. 2004;9:385–97.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Newsome PN, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018 Jan;67(1):6–19.  https://doi.org/10.1136/gutjnl-2017-314924.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician. 2012;86(11):1027–34. quiz 1010–1012PubMedPubMedCentralGoogle Scholar
  29. 29.
    Dienstag JL. Acute viral hepatitis. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J, editors. Harrison’s principles of internal medicine. 19th ed. New York, NY: McGraw-Hill; 2015. isbn:978-0-07-180215-4.Google Scholar
  30. 30.
    Liang TJ. Hepatitis B: the virus and disease. Hepatology (Baltimore, MD). 2009;49(5 Suppl):S13–21.CrossRefGoogle Scholar
  31. 31.
    Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602.CrossRefGoogle Scholar
  32. 32.
    Lok A, McMahon B, Brown R, Wong JB, Ahmed HT, Wigdan F, et al. Antiviral therapy for chronic hepatitis B virus infection in adults: a systematic review and meta-analysis. Hepatology. 2015;63:284–06.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    CDC (2009) Guidelines for viral hepatitis surveillance and case management. http://www.cdc.gov/hepatitis/Statistics/SurveillanceGuidelines.htm. Accessed 26 Nov 2011
  34. 34.
    Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Rutherford A, Dienstag JL. Viral hepatitis. In: Greenberger NJ, Blumberg RS, Burakoff R, editors. Current diagnosis & treatment: gastroenterology, hepatology, & endoscopy. 3rd ed. New York, NY: McGraw-Hill; 2016. isbn:978-0-07-183772-9.Google Scholar
  36. 36.
    Khalili M, Burman B. Liver disease. In: Hammer GD, McPhee SJ, editors. Pathophysiology of disease: an introduction to clinical medicine. 7th ed. New York, NY: McGraw-Hill; 2013.Google Scholar
  37. 37.
    Hsieh TH, Liu CJ, Chen DS, Chen PJ. Natural course and treatment of hepatitis D virus infection. J Formos Med Assoc. 2006;105:869–81.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Menon KV, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc. 2001;76(10):1021–9.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017;38(2):147–61.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Fontana R, Hayashi P. Clinical features, diagnosis, and natural history of drug-induced liver injury. Seminars in liver disease. 2014;34(2):134–44.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Bynum TE, Boitnott JK, Maddrey WC. Ischemic hepatitis. Dig Dis Sci. 1979;24:129–35.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Fuchs S, Bogomolski-Yahalom V, Paltiel O, Ackerman Z. Ischemic hepatitis: clinical and laboratory observations of 34 patients. J Clin Gastroenterol. 1998;26:183–6.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369:2525–34.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Czaja AJ. Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver. 2016;10:177–203.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. 2017;9:715–32.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328–43.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Physician. 2013;87:183–90.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Stoller JK, Aboussouan LS. A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185:246–59.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology. 2003;37:1475–92.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–73.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375:1161–70.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis—a comprehensive review. J Hepatol. 2017;67(6):1298–323.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749–61.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–51.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Procopet B, Berzigotti A. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep. 2017;5(2):79–89.CrossRefGoogle Scholar
  58. 58.
    Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375:767–77.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823–32.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Haq I, Tripathi D. Recent advances in the management of variceal bleeding. Gastroenterol Rep. 2017;5:113–26.CrossRefGoogle Scholar
  61. 61.
    Villanueva C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11–21.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Ferenci P. Hepatic encephalopathy. Gastroenterol Rep. 2017;5(2):138–47.CrossRefGoogle Scholar
  63. 63.
    Sharma BC, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458–63.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Porres-Aguilar M, Altamirano JT, Torre-Delgadillo A, Charlton MR, Duarte-Rojo A. Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. Eur Respir Rev. 2012;21:223–33.CrossRefGoogle Scholar
  65. 65.
    Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis—bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41:1116–31.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Sort P, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–9.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Ng CKF, Chan MHM, Tai MHL, Lam CWK. Hepatorenal syndrome. Clin Biochem Rev. 2007;28:11–7.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Ferenci P, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239–45.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma. Analysis based in serum αfetoprotein levels. J Clin Gastroenterol. 2000;31(4):302–8.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Hanazaki K, Kajikawa S, Koide N, Adachi W, Amano J. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol. 2001 Apr;96(4):1243–50.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl. 2006;12:1049–61.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: the model for end-stage liver disease–should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005;22(11–12):1079–89.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008;28:110–22.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Weng Y, Cui Y, Fang J. Biological functions of cytokeratin 18 in cancer. Mol Cancer Res. 2012;10:485–93.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Maher MM, Ibrahim WA, Saleh SA, Shash L, Abou Gabal H, Tarif M, et al. Cytokeratin 18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients. Egypt J Med Hum Genet. 2015;16(1):41–6.  https://doi.org/10.1016/j.ejmhg.2014.11.003.CrossRefGoogle Scholar
  81. 81.
    Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology. 2009;50:1072–8.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402–7.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467–77.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Loosen SH, Schueller F, Trautwein C, et al. Role of circulating microRNAs in liver diseases. World J Hepatol. 2017;9:586–94.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    El-Ahwany E, Nagy F, Zoheiry M, Shemis M, Nosseir M, Taleb HA, El Ghannam M, Atta R, Zada S. Circulating miRNAs as predictor markers for activation of hepatic stellate cells and progression of HCV-induced liver fibrosis. Electr Phys. 2016;8(1):1804–10.CrossRefGoogle Scholar
  86. 86.
    Wu X, Wu S, Tong L, Luan T, Lin L, Lu S, et al. MiR-122 affects the viability and apoptosis of hepatocellular carcinoma cells. Sci J Gastroenterol. 2009;44:1332–9.CrossRefGoogle Scholar
  87. 87.
    Sato K, Meng F, Glaser S, Alpini G. Exosomes in liver pathology. J Hepatol. 2016;65:213–21.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22:845–54.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Tan CY, Lai RC, Wong W, Dan YY, Lim SK, Ho HK. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther. 2014;5:76.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of MedicineUC Irvine HealthOrangeUSA

Personalised recommendations